Kairos Pharma Reports Increased Net Loss and Operating Expenses for First Half of 2025

Kairos Pharma, Ltd. reported its financial results for the six months ending June 30, 2025, revealing a net loss of $2.684 million, a significant increase from the $576,000 loss recorded during the same period in 2024. The company has not generated any revenue during this period, consistent with its status as a clinical-stage biopharmaceutical firm focused on developing immunotherapy and cell therapy treatments for oncology. Operating expenses for the first half of 2025 totaled $2.722 million, up from $514,000 in the prior year, driven primarily by increased research and development costs associated with ongoing clinical trials.

The company's cash and cash equivalents rose to $3.034 million as of June 30, 2025, compared to $1.272 million at the end of 2024. This increase was bolstered by net proceeds of $3.058 million from a private financing round and $223,000 from its Equity Line of Credit (ELOC). The total assets of Kairos Pharma increased to $6.673 million, up from $5.768 million at the end of the previous fiscal year. Shareholders' equity also improved, reaching $5.997 million, compared to $4.776 million at the end of 2024.

In terms of operational developments, Kairos Pharma has made strategic advancements, including the initiation of Phase 1 and Phase 2 clinical trials for its product candidates, ENV 105 and KROS 201. The company has also entered into several vendor agreements to support its clinical research efforts, including contracts with Prevail Infoworks and PreCheck Health Services. As of June 30, 2025, the company had 17.7 million shares of common stock outstanding, an increase from 13.7 million shares at the end of 2024, reflecting its ongoing capital-raising efforts.

The filing indicates that the company anticipates continued operating losses as it progresses through clinical trials and seeks regulatory approvals for its product candidates. Kairos Pharma expects its current cash reserves to sustain operations for at least the next 12 months, but it will need to secure additional funding to support its growth strategy and operational needs. The company has expressed uncertainty regarding its ability to raise future capital, which could impact its ability to continue operations and pursue its development goals.

Overall, Kairos Pharma's financial performance reflects the challenges faced by early-stage biotechnology companies, including the need for substantial funding and the inherent risks associated with drug development. The company remains focused on advancing its clinical programs while navigating the complexities of the biopharmaceutical landscape.